现代心脏病学中的起器及其从传统模型到无模型的转变
Yusuf Ali Serbetci1, Shelly Jaryal2, Ira Bhasin3
1Internal Medicine, Lokman Hekim University, Ankara, TUR.
Cureus
|May 14, 2025
概括
无心脏起器 (LCP) 通过减少并发症,提供比传统起器更好的结果. 未来的创新有望在心律管理方面取得进一步的进步.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 心脏节律障碍是全球重要的健康问题.
- 起器对于管理这些情况至关重要,因为技术在不断发展.
研究的目的:
- 审查心脏起器技术从传统心脏起器 (TCP) 到无心脏起器 (LCP) 的演变.
- 为了比较植入技术,并发症概况和临床性能.
- 探索心脏起器技术的未来进展.
主要方法:
- 这是一个叙事综述,综合了当前的证据.
- 强调了TCP和LCP之间的关键区别.
- 探讨了最近的进展和未来的潜力.
主要成果:
- 传统的起器面临着诸如相关的并发症和感染等挑战.
- 无心脏起器,植入的最小侵入性,降低风险,提高患者满意度,并降低住院率.
- 尽管LCP的初始成本较高和单室限制,但可能会提供长期的成本效益.
结论:
- 无心脏起器技术显著提高了心律管理的安全性和有效性.
- 新兴的创新,如多元组件系统和能量收集,对未来的心脏护理有很大的希望.
- 无系统,监管批准和个性化管理的趋势将彻底改变心脏护理.
相关概念视频
01:25Dysrhythmias VI: Management of Dysrhythmias
595
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
595
01:29Cardiomyopathy V: Interprofessional Care
750
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
750